Core Insights - NVIDIA CEO Jensen Wong indicated that the company's investment in OpenAI is likely capped at $30 billion, dismissing the possibility of a $100 billion investment due to OpenAI's potential IPO by year-end [2][3] - Wong described this as possibly the last opportunity for NVIDIA to invest in a company like OpenAI, suggesting a shift in the investment landscape as public markets are expected to take precedence [3][4] Investment Details - NVIDIA's investment in OpenAI is limited to $30 billion, with the CEO stating that a larger investment is not feasible due to the impending IPO [2] - The previous discussions regarding a $100 billion deal appear to have stalled, leading to a more straightforward investment structure [3] - NVIDIA's $10 billion investment in Anthropic is also likely to be its last before the anticipated IPO, indicating a broader trend of reduced private investments in AI labs [4]

Well, Jensen Wong making news like he said, specifically at the Morgan Stanley Tech Conference. The Nvidia CEO saying that $30 billion is likely as far as his company goes when it comes to investing in OpenAI. He said, quote, "The opportunity to invest $100 billion in OpenAI is probably not in the cards." And the reason for his statement is that OpenAI is heading towards an IPO potentially by year end, which would close the window on private ini investment at that scale.Nvidia's CEO also called this quote t ...

U.S. equity markets staged a significant recovery on Wednesday, March 4, 2026, as investors processed a batch of resilient labor data and found relief in stabilizing energy prices. Following a period of intense volatility driven by the ongoing conflict in the Middle East, the major indices demonstrated broad-based strength, led by a resurgence in the technology sector. The market's "fear gauge," the VIX, collapsed over 10% to settle at 21.12, signaling that while caution remains elevated, the immediate pani ...

Key Takeaways PLTR posted 70% revenue growth, driven by soaring AIP demand across U.S. commercial and government clients.PLTR reported $609M GAAP net income and sees 2026 revenue rising to $7.198B from $4.475B in 2025.NVDA trades at 24.68x forward earnings vs. Palantir's 108.41x, making NVIDIA relatively more attractive.Riding the wave of artificial intelligence (AI)-driven momentum, Palantir Technologies Inc. (PLTR) and NVIDIA Corporation (NVDA) delivered strong revenue growth and profitability in their la ...

PresentationWow, no music, no walk on music, no roaring applause. I'm just saying, I'm not used to coming to work in this way, this total silence. I'm just kidding.Unknown Analyst Humor is very allowed. I made investment banking jokes yesterday, Jensen. But, thank you for being here for the last, I think, 25, 27 years, you've been such a great supporter of this conference. I think we sometimes become numb to the scale of the numbers and the transformation we're experiencing. I don't think I'm the only one i ...

Core Viewpoint - The article suggests that while AI stocks are experiencing a downturn, biotech stocks, particularly Eli Lilly, present a compelling investment opportunity due to their potential for AI-assisted drug discovery and strong market positions in existing drug markets [1]. Company Analysis - **Eli Lilly (LLY)**: - The stock has seen a decline of approximately 7% year-to-date, but it remains a leader in the GLP-1 drug market with products like Zepbound and Mounjaro [1]. - Eli Lilly's partnership with Nvidia, valued at $1 billion, aims to enhance AI-assisted drug discovery, positioning the company for future growth [1]. - The stock is currently trading at a forward price-to-earnings (P/E) ratio of under 30, which is considered attractive given its potential for AI integration and existing revenue streams from GLP-1 drugs [1]. Industry Insights - The article highlights a shift in investor sentiment away from AI stocks due to rising capital expenditures and concerns over return on investment (ROI) [1]. - Biotech is identified as a sector that could benefit significantly from AI advancements, with the potential for transformative impacts on drug discovery and development processes [1]. - The article emphasizes the importance of diversifying investments into biotech as a counterbalance to the volatility seen in AI-driven tech stocks [1].

Market Overview - The market has experienced significant volatility since the onset of the Iran War, which is consistent with historical patterns observed during previous Gulf Wars [2][15] - Recent market activity has shown a more orderly selloff, indicating a potential sigh of relief among investors [3] Nvidia Insights - Nvidia is viewed as a key player in the AI infrastructure revolution, with the company well-positioned for growth [5] - The stock's forward earnings multiple has decreased from over 38 times to approximately 21 times, reflecting its strong growth and performance [6] - The long-term potential of artificial intelligence is expected to unfold over a decade, presenting opportunities for strategic investments at favorable prices [7] Eli Lilly Analysis - Eli Lilly has excelled in the GLP-1 and weight loss diabetes management market, outperforming competitors like Novo Nordisk [8] - The company is expected to benefit from a growing market, with user numbers projected to increase significantly over the coming years [9] - Eli Lilly's strategy involves a two-phase approach to weight loss management, starting with injectables and transitioning to oral medications, which could resemble the business model of statins [10] Other Tech Stocks - The company also holds positions in other tech stocks, including Palantir, which is recognized for its innovative use of AI in software solutions [12][13] - Palantir is considered a disruptor in the software industry, aiding clients in digitizing processes for better decision-making [13][14] Geopolitical Impact - Historically, geopolitical events like the Iran War have led to short-lived market sell-offs, with the S&P 500 showing resilience over the long term [15][16] - Current economic indicators, such as job growth and inflation, suggest that the market remains fundamentally strong despite geopolitical tensions [17]

责任编辑：李桐 英伟达首席执行官黄仁勋表示，他预计公司对OpenAI的投资不会达到1000亿美元 —— 这是这家芯片制 造商此前曾承诺考虑投入这家初创公司的最高金额。 "我认为投资1000亿美元给OpenAI的机会可能已经不存在了，"黄仁勋表示，这是因为OpenAI计划上 市，可能会在年底前。"因此，这可能是我们最后一次有机会投资这样一家具有影响力的公司。" 上月，英伟达在OpenAI规模达1000亿美元的融资轮中投入了300亿美元，这家ChatGPT开发商的估值达 到7300亿美元。尽管这是英伟达迄今为止对初创公司的最大单笔投资，但远低于该公司9月与OpenAI达 成协议时的承诺，当时公司曾表示考虑投入最高1000亿美元。 黄仁勋还表示，英伟达最近向OpenAI竞争对手Anthropic投资100亿美元，可能也将是对其最后一笔投 资。Anthropic同样在为自身的首次公开募股铺路。 责任编辑：李桐 英伟达首席执行官黄仁勋表示，他预计公司对OpenAI的投资不会达到1000亿美元 —— 这是这家芯片制 造商此前曾承诺考虑投入这家初创公司的最高金额。 "我认为投资1000亿美元给OpenAI的机会可能已经不存 ...

Nvidia CEO Jensen Huang doesn’t see his company’s investments in OpenAI reaching $100 billion — the maximum amount that the chipmaking giant had once pledged to spend on the startup https://t.co/nwnHXfprYy ...

Market OverviewU.S. equity markets are staging a significant recovery during Wednesday afternoon trading, as investors look past recent geopolitical volatility to focus on resilient domestic economic data and a cooling in energy prices. After a sharp sell-off on Tuesday driven by escalating tensions in the Middle East, the major indexes have trended steadily higher throughout the session. As of mid-afternoon, the S&P 500 (SPX) is up approximately 0.85%, trading near the 6,875 level. The tech-heavy Nasdaq Co ...